Rhythm Pharmaceuticals (RYTM) PT Lowered to $16 at Goldman Sachs, Following Earnings
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Price: $115.48 -0.47%
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $16.00 (from $23.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UK regulator expands Imcivree approval to hypothalamic obesity
- Tata Motors Passenger Vehicles (TMPV:IN) PT Raised to INR375 at ICICI Securities
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
